Magenta In The News

May 3, 2017 

Magenta Therapeutics gets $50 million in funding (Boston Globe)

 

May 2, 2017

Building a biotech: Magenta opens up Chapter 2 with a triple play (Blog post by Jason Gardner @ LifeSciVC.com)

Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it (Endpoints News)

Magenta Nabs More Cash, Licenses Drug To Boost Transplant Pipeline (Xconomy)

A $50 Million Bet on Stem-Cell Therapy (Wall Street Journal Venture Capital Pro)

Magenta gains $50M Series B, Novartis candidate and new partnership (FierceBiotech)

 

April 11, 2017

Magenta named one of Nature Biotechnology’s top academic spinouts of 2016 (Nature Biotechnology)

 

November 16, 2016

Rebooting The Conversation (Blog post by Jason Gardner @ LifeSciVC.com)

GSK vet Jason Gardner takes the helm of Magenta, emerging from stealth with a $48.5M round (Endpoints)

Atlas, Third Rock join forces to launch new stem cell upstart (FierceBiotech)

Harvard Spinout Magenta, Other Academics Race Toward Better Stem Cell Transplants (Xconomy)

Stem Cell Transplant Startup With Harvard Tech, Magenta Therapeutics, Gets $48.5M (Forbes)

Magenta Therapeutics Announces $48.5M Series A Financing to Transform Stem Cell Transplant for Immune and Blood Diseases (Yahoo Finance)

Magenta Therapeutics Closes $49 for Blood Stem-Cell Therapy (WSJ Pro Venture Capital)

Stem cell startup Magenta launches with $48.5m (MedCityNews)

Two venture firms launch Cambridge biotech with $48.5m in funding (Boston Globe)

Tackling blood diseases, immune disorders (Harvard Gazette)

Atlas, Third Rock launch new Cambridge biotech with $49M round (Boston Business Journal)

Tackling blood diseases, immune disorders (EurekAlert)

 

July 15, 2016

Standing on the shoulders of stem cell gene therapists (MedCityNews – July 15)